Yes, that is me in the picture. Not the young ones! God bless your neighborhood pharmacy and your rubgy field. I would prefer if you did not waste my time. If you boys waste my time, then I will set your magnetar trade(s) on the sirena. Sirenas like those mermaids, they have a lot of liquidity protecting them--so better not to try and contact my singularity.
Mr. Aberman joined Pluristem as Chairman & CEO in September 2005. Upon arrival he immediately changed the Company’s strategy towards cellular therapeutics. Mr. Aberman's vision to use the maternal section of the Placenta (Decidua) as a source for cell therapy, combined with Pluristem’s 3D culturing technology, led to the development of a series of unique products.
Mr. Aberman has 20 years of experience in marketing and management within the high technology industry. He has held positions as Chief Executive Officer and Chairman in Israel, the USA, Europe, Japan and Korea. He has operated within high-tech global companies in the fields of automatic optical inspection, network security, video over IP, software, chip design and robotics. Mr. Aberman serves as the Chairman of Rose Hitech Ltd., a private investment company. He has served in the past as the Chairman of VLScom Ltd., a private company specializing in video compression for HDTV and video over IP and as a Director of Ori Software Ltd., a company involved in data management. Prior to that, he served as the President and CEO of Elbit Vision Systems (EVSNF.OB), which supplies inspection systems for the microelectronic industry.
Mr. Aberman has served as President and CEO of Netect Ltd., specializing in the field of internet security software and was the Co-Founder, President and CEO of Associative Computing Ltd., which developed an associative parallel processor for real-time video processing. He has also served as Chairman of Display Inspection Systems Inc., specializing in laser based inspection machines and as President and CEO of Robomatix Technologies Ltd. (RBMXF.OB).
In 1992, Mr. Aberman was awarded the Rothschild Prize for excellence in his field from the President of the State of Israel.
Mr. Aberman holds a B.Sc. in Mechanical Engineering from Ben Gurion University in Israel.
Sharon di Stefano has spent 20 years as an analyst, beginning her career at Smith Barney, Harris Upham & Co. specializing in medical devices, pharmaceuticals, healthcare information technology, and biopharmacology. Ms. di Stefano had also served as Senior Venture Officer for the Edison Innovation Fund, implemented through the New Jersey Economic Development Authority that provided funding for early-stage life sciences companies. Industry experience includes laboratory research for Johns Hopkins Hospital and the Department of Defense.
Ms. di Stefano received a Masters of Science degree, in Business, from Johns Hopkins University in 1986, and a Bachelor of Arts from the University of Delaware in 1984 with a minor in biology.